Overview

Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study objectives of this study are to determine the effects, safety, and pharmacokinetics of bendamustine for multiple myeloma to a regimen of bendamustine and prednisolone.
Phase:
Phase 2
Details
Lead Sponsor:
SymBio Pharmaceuticals
Treatments:
Bendamustine Hydrochloride
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate